Patients Can Administer Mobile Audio Recordings to Increase Knowledge in Advanced Prostate Cancer.

Autor: Kwon DH; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA., Trihy L; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA., Darvish N; Department of Surgery, University of California, San Francisco, California, USA., Hearst E; Department of Surgery, University of California, San Francisco, California, USA.; Geisel School of Medicine, Hanover, New Hampshire, USA., Sumra S; Department of Surgery, University of California, San Francisco, California, USA., Borno HT; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA., Bose R; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA., Chou J; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA., de Kouchkovsky I; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA., Desai A; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA., Ekstrand B; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA., Friedlander T; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA., Kaur G; Department of Surgery, University of California, San Francisco, California, USA., Koshkin VS; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA., Nesheiwat S; Department of Surgery, University of California, San Francisco, California, USA., Sepucha K; Harvard Medical School, Boston, Massachusetts, USA., Small EJ; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA., Aggarwal RR; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA., Belkora J; Department of Surgery, University of California, San Francisco, California, USA.; Institute for Health Policy Studies, University of California, San Francisco, California, USA.

Publikováno v: Cancer medicine [Cancer Med] 2024 Nov; Vol. 13 (22), pp. e70433.

Diagnosis and management of neuroendocrine prostate cancer.

Autor: de Kouchkovsky I; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.; Department of Medicine, Division of Hematology and Oncology, University of California San Francisco, San Francisco, California, USA., Chan E; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.; Department of Pathology, University of California San Francisco, San Francisco, California, USA., Schloss C; Merck & Co., Inc., Rahway, New Jersey, USA., Poehlein C; Merck & Co., Inc., Rahway, New Jersey, USA., Aggarwal R; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.; Department of Medicine, Division of Hematology and Oncology, University of California San Francisco, San Francisco, California, USA.

Publikováno v: The Prostate [Prostate] 2024 Apr; Vol. 84 (5), pp. 426-440. Date of Electronic Publication: 2024 Jan 03.

Initial Experience with ⁶⁸ Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer.

Autor: Koshkin VS; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California; vadim.koshkin@ucsf.edu.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California; and., Kumar V; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California., Kline B; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California., Escobar D; Department of Urology, University of California San Francisco, San Francisco, California., Aslam M; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California., Cooperberg MR; Department of Urology, University of California San Francisco, San Francisco, California., Aggarwal RR; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California; and., de Kouchkovsky I; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California; and., Chou J; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California; and., Meng MV; Department of Urology, University of California San Francisco, San Francisco, California., Friedlander T; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California; and., Porten S; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California; and.; Department of Urology, University of California San Francisco, San Francisco, California., Hope TA; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California; and.

Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2024 Feb 01; Vol. 65 (2), pp. 199-205. Date of Electronic Publication: 2024 Feb 01.

Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.

Autor: Jindal T; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Zhang L; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Deshmukh P; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Reyes K; Department of Medicine, School of Medicine, University of California San Francisco, San Francisco, CA., Chan E; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Kumar V; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Zhu X; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Maldonado E; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Feng S; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Johnson M; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Angelidakis A; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Kwon D; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Desai A; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Borno HT; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Bose R; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Wong A; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Hong J; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Carroll P; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Meng M; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Porten S; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Aggarwal R; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Small EJ; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Fong L; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Chou J; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Friedlander T; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., de Kouchkovsky I; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA. Electronic address: Ivan.DeKouchkovsky@ucsf.edu., Koshkin VS; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA. Electronic address: Vadim.koshkin@ucsf.edu.

Publikováno v: Clinical genitourinary cancer [Clin Genitourin Cancer] 2023 Oct; Vol. 21 (5), pp. e394-e404. Date of Electronic Publication: 2023 May 17.

Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer.

Autor: Jindal T; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Zhu X; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Bose R; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Kumar V; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Maldonado E; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Deshmukh P; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Shipp C; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Feng S; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Johnson MS; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Angelidakis A; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Kwon D; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Borno HT; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., de Kouchkovsky I; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Desai A; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Aggarwal R; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Fong L; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Small EJ; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Wong A; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Porten S; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Chou J; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Friedlander T; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Koshkin VS; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.

Publikováno v: Frontiers in oncology [Front Oncol] 2023 Apr 05; Vol. 13, pp. 1161089. Date of Electronic Publication: 2023 Apr 05 (Print Publication: 2023).